Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study

Tabata, Ami; Kanai, Masashi; Horimatsu, Takahiro; Tsuboyama, Tadao; Matsushima, Kanae; Kato, Toshihiro

doi:10.1007/s00520-018-4070-z

Cited by 18 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When examining changes from baseline to 1 month or longer following chemotherapy completion, four studies reported recovery to baseline levels and one study reported no longitudinal changes, suggesting an acute impact of chemotherapy on SCI. In contrast, five studies reported no significant change from baseline to active treatment or within 1 month after treatment, mostly in non–breast‐cancer samples . Seven studies reported the prevalence of significant cognitive decline after initiating chemotherapy (from 11% to 37%) .…”

Section: Resultsmentioning

confidence: 96%

“…These modeling techniques are strong in examining the association of changing patterns of dependent and moderator variables and may provide more robust and conclusive evidence of moderating effects in the chemotherapy‐SCI relationship. Researchers also used paired t tests, repeated‐measures analysis of variance (ANOVA)/multivariate analysis of variance (MANOVA), and the nonparametric Kruskal‐Wallis test to compare mean differences of SCI at two or more time points in one or more groups. When using analytical approaches based on group means, individual variability in longitudinal changes over time may not be considered fully; mean change may be underestimated because of sample variability .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

et al. 2020

View full text Add to dashboard Cite

Objectives: This systematic review of longitudinal studies, assessing subjective cognitive impairment (SCI) reported by adult cancer patients, aimed to summarize evidence on the impact of chemotherapy on SCI, identify moderators of SCI, and evaluate methodological issues. Methods: Data accrued from Pubmed, EMBASE, CINAHL, PsychInfo, and the Cochrane library. Inclusion criteria were original studies, an exclusively adult sample, valid and reliable subjective cognitive measures, and at least one baseline data point prior to and another after the initiation of chemotherapy. Data were collected on the sample composition, data-collection time points, outcome measures, statistical analysis, and major findings (ie, longitudinal changes in prevalence, severity, and associated factors).Results: Forty articles published between 2004 and 2019 were retained: 21 examined chemotherapy-treated patients only, and 19 employed control groups. Findings were mixed, with slightly more studies supporting the impact of chemotherapy on SCI. SCI tended to be more prevalent and severe after initiating chemotherapy, compared with patients' own baseline and controls not treated with chemotherapy. Impact appeared to be acute and more likely limited to subsamples. Most studies examining non-breast-cancer samples reported the lack or limited impact of chemotherapy on SCI. The most consistent moderators were depression and fatigue. Methodological issues regarding sampling design, measurement, and statistical analysis were discussed.Conclusion: More rigorously designed longitudinal studies would clarify direct and indirect effects of chemotherapy on SCI. K E Y W O R D S anxiety, cancer, cognitive function, cognitive impairment, depression, fatigue, oncology, systematic review

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The influence of chemotherapy as a cancer treatment modality on patient health-related QoL has been widely investigated (Chagani et al, 2017; de Jong et al, 2006; García-García et al, 2019; Mosconi et al, 2002; Sasaki et al, 2017). However, only few studies examined the impact of first-cycle (FC) chemotherapy on their QoL (Charalambous et al, 2017; Hoppe et al, 2013; Tabata et al, 2018), and no study had been conducted among the Saudi population. Raising the importance of assessing the QoL of patients with cancer during the first stage of chemotherapeutic management provides impetus to develop evidence-based and individualized supportive care along the course of cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life Among Breast and Colon Cancer Patients Before and After First-Cycle Chemotherapy

Zamel

Inocian

Alshehry³

et al. 2020

J Holist Nurs

View full text Add to dashboard Cite

Purpose: This study aimed to compare the functioning, symptoms, and quality of life (QoL) of patients with breast or colon cancer before and after their first-cycle (FC) chemotherapy. Design: One-group pretest/posttest design. Method: The study utilized the standardized Arabic-translated Quality of Life Questionnaire Version 3 from the European Organization for Research and Treatment of Cancer in measuring the functioning, symptoms, and QoL of 120 Saudi patients diagnosed with breast or colon cancer. Dependent t test was used in analyzing the presence of significant differences in mean scores before and after chemotherapy with periods ranging from 14 days to 21 days following the treatment protocol. Results: The findings revealed significant differences in the functioning, symptoms, and QoL among patients with breast or colon cancer before and after FC chemotherapy ( p < .001). Baseline scores showed higher physical, role, emotional, cognitive, and social functioning; lesser symptoms; lower financial difficulties; and better overall global health status compared to post-FC chemotherapy. Conclusion: Assessing the QoL of patients with breast or colon cancer undergoing FC chemotherapy is essential to establish a holistic care plan in supporting and alleviating the unfavorable effects of chemotherapy and implement patient-centered interventions that aid in the enhancement of their overall QoL.

show abstract

“…Increased oxidative stress is detrimental for muscle mass and for functional capacity [16,42,43,44].…”

Section: Discussionmentioning

confidence: 99%

Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study

et al. 2019

View full text Add to dashboard Cite

Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2’-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (p = 0.017, p = 0.028, p = 0.028, respectively). Plasma levels of MOS did not change significantly. This study indicates that XELOX therapy does not affect plasma AA levels or worsen oxidative stress.

show abstract

Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study

Cited by 18 publications

References 35 publications

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

Quality of Life Among Breast and Colon Cancer Patients Before and After First-Cycle Chemotherapy

Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study

Contact Info

Product

Resources

About